The Company was founded in 2008 by a group of Polish scientists who have developed a breakthrough method of using liquid crystals for diagnosing breast cancer. The researchers have created a unique mixture of liquid crystal compounds and an innovative liquid crystal emulsion formula that have been used to develop a signature method of manufacturing liquid crystal matrices using Continuous Liquid Crystals Film (CLCF) technology. The objective of the Company’s activities is the roll-out of the TESTER, an innovative, worldwide-unique device for early diagnostics of breast cancer.
The results of research performed in 2009-2010 gave rise to registering the device in 2010 with the Office for Registration of Medicinal Products, Medical Devices and Biocides as a class I medical device. Upon registration, the Company was free to sell the product to the markets of the European Union countries. In 2011 the TESTER was submitted to EUDAMED, a European database for medical devices maintained by the European Commission.
As part of its R&D activities, in 2013-2014 the Company conducted an observation test called THERMACRAC, comparing the efficacy of the TESTER in diagnostics and differentiating breast pathologies in women as compared to standard diagnostics methods. The tests proved that the device is useful in diagnosing breast pathologies in women, and the sensitivity and specificity results confirmed its efficacy.
BRASTER SA cooperates with leading national research centres that have extensive experience in studying the structure and applications of liquid crystals, which are used in research conducted by BRASTER SA In addition, the Company cooperates with the Medical College of the Jagiellonian University, which participated in the THERMACRAC clinical trial.
BRASTER was awarded by the Polish Federation of Engineering Associations with Golden Laurel of Innovation, by the Gazeta Prawna daily with the prestigious title of Market Leader of Innovation and in the Polish Product of the Future competition organised by the Polish Agency for Enterprise Development.
In 2012 the Company was listed for public subscription on the NewConnect market.